Table_1_High Glycemic Diet Is Related to Brain Amyloid Accumulation Over One Year in Preclinical Alzheimer's Disease.PDF

Objective: To test the hypothesis that high glycemic diet is related to 1-year change in brain amyloid based on our prior cross-sectional evidence that high glycemic diet is associated with brain amyloid.Methods: This longitudinal, observational study assessed the relationship between reported habitual consumption of a high glycemic diet (HGDiet) pattern and 1-year brain amyloid change measured by Florbetapir F18 PET scans in 102 cognitively normal older adults with elevated or sub-threshold amyloid status that participated in a 1-year randomized, controlled exercise trial at the University of Kansas Medical Center in Kansas City.Results: Among all participants (n = 102), higher daily intake of the HGDiet pattern (β = 0.06, p = 0.04), sugar (β = 0.07, p = 0.01), and total carbohydrate (β = 0.06, p = 0.04) were related to more precuneal amyloid accumulation. These relationships in the precuneus were accentuated in participants with elevated amyloid at enrollment (n = 70) where higher intake of the HGDiet pattern, sugar, and carbohydrate were related to more precuneal amyloid accumulation (β = 0.11, p = 0.01 for all measures). In individuals with elevated amyloid, higher intake of the HGDiet pattern was also related to more amyloid accumulation in the lateral temporal lobe (β = 0.09, p Conclusion: This longitudinal observational analysis suggests that a high glycemic diet relates to higher brain amyloid accumulation over 1 year in regions of the temporoparietal cortex in cognitively normal adults, particularly in those with elevated amyloid status. Further studies are required to assess whether there is causal link between a high glycemic diet and brain amyloid.Clinical Trial Registration:ClinicalTrials.gov, Identifier (NCT02000583).</p

Table_2_High Glycemic Diet Is Related to Brain Amyloid Accumulation Over One Year in Preclinical Alzheimer's Disease.PDF

Objective: To test the hypothesis that high glycemic diet is related to 1-year change in brain amyloid based on our prior cross-sectional evidence that high glycemic diet is associated with brain amyloid.Methods: This longitudinal, observational study assessed the relationship between reported habitual consumption of a high glycemic diet (HGDiet) pattern and 1-year brain amyloid change measured by Florbetapir F18 PET scans in 102 cognitively normal older adults with elevated or sub-threshold amyloid status that participated in a 1-year randomized, controlled exercise trial at the University of Kansas Medical Center in Kansas City.Results: Among all participants (n = 102), higher daily intake of the HGDiet pattern (β = 0.06, p = 0.04), sugar (β = 0.07, p = 0.01), and total carbohydrate (β = 0.06, p = 0.04) were related to more precuneal amyloid accumulation. These relationships in the precuneus were accentuated in participants with elevated amyloid at enrollment (n = 70) where higher intake of the HGDiet pattern, sugar, and carbohydrate were related to more precuneal amyloid accumulation (β = 0.11, p = 0.01 for all measures). In individuals with elevated amyloid, higher intake of the HGDiet pattern was also related to more amyloid accumulation in the lateral temporal lobe (β = 0.09, p Conclusion: This longitudinal observational analysis suggests that a high glycemic diet relates to higher brain amyloid accumulation over 1 year in regions of the temporoparietal cortex in cognitively normal adults, particularly in those with elevated amyloid status. Further studies are required to assess whether there is causal link between a high glycemic diet and brain amyloid.Clinical Trial Registration:ClinicalTrials.gov, Identifier (NCT02000583).</p

Supplemental Tables 1-5 from Omega-3 and Omega-6 Fatty Acids in Blood and Breast Tissue of High-Risk Women and Association with Atypical Cytomorphology

Supplemental Tables 1-5. Supplemental Table 1: comparison of fatty acid composition by cytologic atypia or not. Supplemental Table 2: Comparison of fatty acid composition of plasma phospholipids (PLs) by evidence of cytology atypia. Supplemental Table 3: Comparison of fatty acid composition of plasma triacylglycerides (TAGs) by evidence of cytology atypia. Supplemental Table 4: Comparison of fatty acid composition of breast phospholipids (PLs) by evidence of cytology atypia. Supplemental Table 5: Comparison of fatty acid composition of breast triacylglycerides (TAGs) by evidence of cytology atypia.</p

Data_Sheet_1_Preliminary Investigation of a Mobile Nutrition Literacy Website for Parents and Young Children.docx

Parental nutrition literacy (PNL) correlates positively with child diet quality, but interventions for improving PNL are lacking. “Nutricity” is a novel bilingual (English/Spanish) mobile tool designed by the research team to engage parents and young children to interact with nutrition information to make nutrition decisions. The purpose of this study was to inform a future intervention through (1) assessing parental likability of Nutricity, and (2) collecting perceptions of pediatric clinic personnel on the feasibility of introducing Nutricity in pediatric clinics. PNL scores and feedback about Nutricity were collected using mixed methods from 15 English-speaking and 15 Spanish-speaking parents of 1–5 year-old children. Three parents from each language group provided additional feedback via semi-structured interviews. Interviews with 11 pediatric clinic personnel were also conducted to anticipate barriers and formulate strategies for implementing Nutricity as a clinic-based intervention. Nutricity was liked by both language groups and across all PNL levels, with a mean rating of 4.6 on a 5-point scale. Clinic personnel interviews affirmed need for and feasibility of offering Nutricity in clinics.</p

Demographic characteristics of 12 individuals with ADPKD who completed interviews after following a dietary intervention trial.

<p>Demographic characteristics of 12 individuals with ADPKD who completed interviews after following a dietary intervention trial.</p

Supplemental Files from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women

Supplemental Figure 1: CONSORT diagram for flow of potential and actual subjects enrolled on study. Supplementary Table 1. Demographic and risk information at baseline. Supplementary Table 2. Change in fatty acid content in all five compartments. Supplementary Table 3. Change in anthropomorphic variables. Supplementary Table 4: Changes in levels of cytokines and adipokines in RPFNA specimens, by Luminex. Supplementary Table 5: Changes in levels of mRNA in RPFNA specimens, by RT-qPCR. Supplementary Table 6: Changes in levels of all peptides and specific phosphopeptides in RPFNA specimens, by Reverse Phase Protein Array.</p

Supplemental Files from Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women

Supplemental Figure 1: CONSORT diagram for flow of potential and actual subjects enrolled on study. Supplementary Table 1. Demographic and risk information at baseline. Supplementary Table 2. Change in anthropomorphic variables. Supplementary Table 3: Changes in levels of cytokines and adipokines in RPFNA specimens, by Luminex. Supplementary Table 4: Changes in levels of mRNA in RPFNA specimens, by RT-qPCR. Supplementary Table 5: Changes in levels of all peptides and specific phosphopeptides in RPFNA specimens, by Reverse Phase Protein Array.</p

Supplementary Tables 1-7 from Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo

Supplemental Table 1: Specimen collection and assay methods details. Supplemental Table 2 Adverse Events Supplemental Table 3. Value and changes in ratio of (DHA+EPA)/AA in erythrocyte phospholipids. Supplemental Table 4. Median relative difference (percent) between baseline and 12 months for 19 serum biomarkers (of a total of 24 assessed) which exhibited a statistically significant change over time* either for the total cohort of 35 women completing the 12-month trial and/or for groups defined by randomization or by dichotomization at 10% weight loss achieved at 6 months. Supplemental Table 5: Biomarker change at 12 months by subgroups defined by randomization arm (placebo vs ω-3 FA) and dichotomization by weight loss (10%). Biomarkers are grouped into categories of adipokines, cytokines, hormones/growth factors, and insulin. A total of 24 biomarkers or ratios were assessed at 12 months. Supplemental Table 6: Levels and changes for adiponectin assessed in serum collected both fasting and non-fasting, and in benign breast tissue acquired non-fasting by RPFNA. Supplemental Table 7: Baseline, 6-month, and 12-month values and change over time for Ki-67, Masood cytomorphology score. -</p